Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Mar;82(3):e56.
doi: 10.1136/annrheumdis-2020-219535. Epub 2020 Dec 4.

Response to: 'Correspondence on 'EULAR definition of difficult-to-treat rheumatoid arthritis'' by Novella-Navarro et al

Nadia M T Roodenrijs  1 , Paco M J Welsing  2 , Marlies C van der Goes  2   3 , Johannes Wg Jacobs  2 , Désirée van der Heijde  4 , Jacob M van Laar  2 , György Nagy  5
Affiliations
Free article
Comment

Response to: 'Correspondence on 'EULAR definition of difficult-to-treat rheumatoid arthritis'' by Novella-Navarro et al

Nadia M T Roodenrijs et al. Ann Rheum Dis. 2023 Mar.
Free article
No abstract available

Keywords: arthritis; inflammation; rheumatoid.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DvdH received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB. JMvL reports personal fees from Arxx Tx, Gesyntha, Magenta, Sanofi Genzyme, Leadiant, Boehringer-Ingelheim and Galapagos; grants and personal fees from Roche; grants from AstraZeneca, MSD and ThermoFisher. GN received fees from Amgen, AbbVie, BMS, Boehringer Ingelheim, Janssen, KRKA, Merck, MSD, Novartis, Pfizer, Roche and UCB; research grants from Pfizer and AbbVie. All competing interests are outside the submitted work.

Comment on

  • EULAR definition of difficult-to-treat rheumatoid arthritis.
    Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Blaas E, Senolt L, Szekanecz Z, Choy E, Dougados M, Jacobs JW, Geenen R, Bijlsma HW, Zink A, Aletaha D, Schoneveld L, van Riel P, Gutermann L, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM. Nagy G, et al. Ann Rheum Dis. 2021 Jan;80(1):31-35. doi: 10.1136/annrheumdis-2020-217344. Epub 2020 Oct 1. Ann Rheum Dis. 2021. PMID: 33004335 Free PMC article.
  • Correspondence on: 'EULAR definition of difficult-to-treat rheumatoid arthritis'.
    Novella-Navarro M, Plasencia-Rodríguez C, Tornero C, Navarro-Compán V, Cabrera-Alarcón JL, Peiteado D, Nuño L, Monjo I, Franco-Gómez K, Villalba A, Balsa A. Novella-Navarro M, et al. Ann Rheum Dis. 2023 Mar;82(3):e55. doi: 10.1136/annrheumdis-2020-219500. Epub 2020 Dec 4. Ann Rheum Dis. 2023. PMID: 33277240 No abstract available.

MeSH terms

Substances